Kilambi News
Saturday, November 21, 2026

FDA rejects Capricor Duchenne cell therapy over data integrity

Life Sciences Friday, November 20, 2026 - Updated Nov 20, 2026 19:23

The FDA has refused to approve Capricor Therapeutics' deramiocel cell therapy for Duchenne muscular dystrophy, issuing a complete response letter that cites serious data integrity violations in the HOPE-3 trial that cannot be remediated after the fact.

Why it matters: The rejection closes a closely watched rare disease application for now and signals that the FDA will not approve a therapy on trial data it considers unreliable, however strong the patient pressure for new Duchenne treatments.

Data as of FDA statement on the deramiocel Biologics License Application, published November 20, 2026 at 6:11 p.m. Eastern; every decision fact and figure is the FDA's own, from its statement. Share price reaction via Reuters. Developing item.

The Food and Drug Administration on Friday issued a complete response letter refusing to approve deramiocel, Capricor Therapeutics’ allogeneic cardiosphere-derived cell therapy for Duchenne muscular dystrophy, saying the evidence does not meet the standard required for approval. The letter cites serious data integrity violations in the conduct of Study HOPE-3, including unauthorized post hoc changes to the statistical analysis plan and violations of study blinding procedures, which the agency said render the data unreliable and incapable of post hoc remediation; HOPE-3 had also failed its pre-specified primary and secondary endpoints.

The decision followed a July 29, 2026 advisory committee meeting and a major amendment in which Capricor added 24-month open-label extension data and changed its proposed indication to upper limb impairment rather than cardiomyopathy, which the FDA said it reviewed before concluding the standard was still not met. The agency also issued a Regulatory Responsibility Letter dated November 20, 2026 over the inspection findings behind the data integrity concerns. Capricor shares fell 72 percent in extended trading, according to Reuters.

Sources

  1. Statement on Deramiocel BLA for Duchenne Muscular Dystrophy - US Food and Drug Administration - 2026-11-20
  2. FDA rejects Capricor Duchenne therapy, a decision that was a long time coming - STAT - 2026-11-20
  3. US FDA declines to approve Capricor's cell therapy for Duchenne muscular dystrophy; shares slump - Reuters - 2026-11-20